[HTML][HTML] Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients
BL Kasiske, A De Mattos, SM Flechner, L Gallon… - American Journal of …, 2008 - Elsevier
The incidence, pathogenesis, consequences and treatment of mammalian target of
rapamycin (mTOR) inhibitor dyslipidemia are not well described. We conducted a systematic
review of randomized controlled trials reporting cholesterol and triglycerides in mTOR
versus non-mTOR inhibitor immunosuppressive treatment regimens in kidney transplant
recipients. All but one of 17 trials reported higher levels of cholesterol and triglycerides, or
an increased prevalence of treatment with lipid-lowering agents. Approximately 60% of …
rapamycin (mTOR) inhibitor dyslipidemia are not well described. We conducted a systematic
review of randomized controlled trials reporting cholesterol and triglycerides in mTOR
versus non-mTOR inhibitor immunosuppressive treatment regimens in kidney transplant
recipients. All but one of 17 trials reported higher levels of cholesterol and triglycerides, or
an increased prevalence of treatment with lipid-lowering agents. Approximately 60% of …